{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:38:51Z","timestamp":1783100331829,"version":"3.54.6"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40265-020-01293-0","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T10:03:02Z","timestamp":1587549782000},"page":"635-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["New and Emerging Therapies for Alopecia Areata"],"prefix":"10.1007","volume":"80","author":[{"given":"Aunna","family":"Pourang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Atanaskova","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985.","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"1","key":"1293_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","volume":"137","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, et al. Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301\u20134. https:\/\/doi.org\/10.1016\/j.jaci.2015.11.001.","journal-title":"J Allergy Clin Immunol."},{"issue":"7","key":"1293_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2340\/00015555-3183","volume":"99","author":"H Uchida","year":"2019","unstructured":"Uchida H, Kamata M, Watanabe A, Agematsu A, Nagata M, Fukaya S, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol. 2019;99(7):675\u20136. https:\/\/doi.org\/10.2340\/00015555-3183.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1293_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","volume":"8","author":"R Paus","year":"2003","unstructured":"Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8(2):188\u201394. https:\/\/doi.org\/10.1046\/j.1087-0024.2003.00807.x.","journal-title":"J Investig Dermatol Symp Proc."},{"issue":"11","key":"1293_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/exd.12489","volume":"23","author":"T Ito","year":"2014","unstructured":"Ito T, Tokura Y. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol. 2014;23(11):787\u201391. https:\/\/doi.org\/10.1111\/exd.12489.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1293_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.1986.tb02825.x","volume":"114","author":"AG Messenger","year":"1986","unstructured":"Messenger AG, Slater DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol. 1986;114(3):337\u201347. https:\/\/doi.org\/10.1111\/j.1365-2133.1986.tb02825.x.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1293_CR7","doi-asserted-by":"publisher","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","volume":"11","author":"AAK de Medeiros","year":"2016","unstructured":"de Medeiros AAK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080. https:\/\/doi.org\/10.1371\/journal.pone.0164080.","journal-title":"PLoS One."},{"issue":"4","key":"1293_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00403-015-1539-1","volume":"307","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhao Y, Ye Y, Li S, Qi S, Yang Y, et al. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res. 2015;307(4):319\u201331. https:\/\/doi.org\/10.1007\/s00403-015-1539-1.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"1293_CR9","first-page":"674","volume":"71","author":"EP Kubeyinje","year":"1994","unstructured":"Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J. 1994;71(10):674\u20135.","journal-title":"East Afr Med J"},{"issue":"1","key":"1293_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-7753.66920","volume":"2","author":"M Kumaresan","year":"2010","unstructured":"Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichology. 2010;2(1):63\u20135. https:\/\/doi.org\/10.4103\/0974-7753.66920.","journal-title":"Int J Trichology."},{"issue":"1","key":"1293_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1067\/mjd.2003.423","volume":"49","author":"A Tosti","year":"2003","unstructured":"Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis. J Am Acad Dermatol. 2003;49(1):96\u20138. https:\/\/doi.org\/10.1067\/mjd.2003.423.","journal-title":"J Am Acad Dermatol."},{"issue":"8\u20139","key":"1293_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.annder.2010.06.002","volume":"137","author":"M Ait Ourhroui","year":"2010","unstructured":"Ait Ourhroui M, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a once-monthly oral pulse [in French]. Ann Dermatol Venereol. 2010;137(8\u20139):514\u20138. https:\/\/doi.org\/10.1016\/j.annder.2010.06.002.","journal-title":"Ann Dermatol Venereol"},{"issue":"5 Pt 1","key":"1293_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0190-9622(98)70048-9","volume":"39","author":"CK Rokhsar","year":"1998","unstructured":"Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5 Pt 1):751\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1293_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/jidsymp.2015.28","volume":"17","author":"KS Chiang","year":"2015","unstructured":"Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc. 2015;17(2):50\u20135. https:\/\/doi.org\/10.1038\/jidsymp.2015.28.","journal-title":"J Investig Dermatol Symp Proc."},{"issue":"8","key":"1293_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00403-019-01940-x","volume":"311","author":"M Nasimi","year":"2019","unstructured":"Nasimi M, Ghandi N, Abedini R, Mirshamsi A, Shakoei S, Seirafi H. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Arch Dermatol Res. 2019;311(8):607\u201313. https:\/\/doi.org\/10.1007\/s00403-019-01940-x.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1293_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.0906-6705.2004.00098.x","volume":"13","author":"L Tang","year":"2004","unstructured":"Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol. 2004;13(1):5\u201310. https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00098.x.","journal-title":"Exp Dermatol"},{"issue":"6398","key":"1293_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/bmj.287.6398.1015","volume":"287","author":"DA Fenton","year":"1983","unstructured":"Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J (Clin Res Ed). 1983;287(6398):1015\u20137. https:\/\/doi.org\/10.1136\/bmj.287.6398.1015.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"1293_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","volume":"150","author":"AG Messenger","year":"2004","unstructured":"Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186\u201394.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1293_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","volume":"80","author":"K Phan","year":"2019","unstructured":"Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(1):120\u2013127e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.064.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"1293_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/15569527.2013.839997","volume":"33","author":"G Acikgoz","year":"2014","unstructured":"Acikgoz G, Caliskan E, Tunca M, Yeniay Y, Akar A. The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol. 2014;33(3):247\u201352. https:\/\/doi.org\/10.3109\/15569527.2013.839997.","journal-title":"Cutan Ocul Toxicol."},{"issue":"2 Pt 1","key":"1293_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/0190-9622(90)70032-d","volume":"22","author":"AK Gupta","year":"1990","unstructured":"Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2 Pt 1):242\u201350. https:\/\/doi.org\/10.1016\/0190-9622(90)70032-d.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"1293_CR22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jaad.2019.04.053","volume":"81","author":"VWY Lai","year":"2019","unstructured":"Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694\u2013701. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.053.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1293_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jdcr.2016.01.005","volume":"2","author":"CV Nissen","year":"2016","unstructured":"Nissen CV, Wulf HC. Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: a case series of 8 patients. JAAD Case Rep. 2016;2(2):117\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2016.01.005.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"1293_CR24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jaad.2013.02.011","volume":"68","author":"F Stephan","year":"2013","unstructured":"Stephan F, Habre M, Tomb R. Successful treatment of alopecia totalis with hydroxychloroquine: report of 2 cases. J Am Acad Dermatol. 2013;68(6):1048\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2013.02.011.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1293_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/s0190-9622(85)70088-6","volume":"12","author":"AJ Mitchell","year":"1985","unstructured":"Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol. 1985;12(4):644\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(85)70088-6.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"1293_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","volume":"336","author":"RS Stern","year":"1997","unstructured":"Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med. 1997;336(15):1041\u20135. https:\/\/doi.org\/10.1056\/NEJM199704103361501.","journal-title":"N Engl J Med."},{"key":"1293_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1687819","author":"AK Gupta","year":"2019","unstructured":"Gupta AK, Carviel JL. Meta-analysis of 308-nm excimer laser therapy for alopecia areata. J Dermatolog Treat. 2019. https:\/\/doi.org\/10.1080\/09546634.2019.1687819.","journal-title":"J Dermatolog Treat."},{"issue":"1","key":"1293_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s1011-1344(02)00280-4","volume":"67","author":"Z Novak","year":"2002","unstructured":"Novak Z, Bonis B, Baltas E, Ocsovszki I, Ignacz F, Dobozy A, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67(1):32\u20138. https:\/\/doi.org\/10.1016\/s1011-1344(02)00280-4.","journal-title":"J Photochem Photobiol B"},{"key":"1293_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jphotobiol.2015.10.015","volume":"153","author":"KP Fernandes","year":"2015","unstructured":"Fernandes KP, Souza NH, Mesquita-Ferrari RA, Silva Dde F, Rocha LA, Alves AN, et al. Photobiomodulation with 660-nm and 780-nm laser on activated J774 macrophage-like cells: effect on M1 inflammatory markers. J Photochem Photobiol B. 2015;153:344\u201351. https:\/\/doi.org\/10.1016\/j.jphotobiol.2015.10.015.","journal-title":"J Photochem Photobiol B"},{"issue":"11","key":"1293_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/1346-8138.13933","volume":"44","author":"S Lee","year":"2017","unstructured":"Lee S, Lee WS. Management of alopecia areata: updates and algorithmic approach. J Dermatol. 2017;44(11):1199\u2013211. https:\/\/doi.org\/10.1111\/1346-8138.13933.","journal-title":"J Dermatol"},{"issue":"8","key":"1293_CR31","first-page":"1063","volume":"137","author":"MC Wiseman","year":"2001","unstructured":"Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137(8):1063\u20138.","journal-title":"Arch Dermatol"},{"key":"1293_CR32","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1038\/jid.2011.267","volume":"132","author":"A Jabbari","year":"2012","unstructured":"Jabbari A, Dai Z, Xing L. Targeting of JAK3 prevents onset of murine alopecia areata. Immunology I: adaptive immunity abstracts. J Invest Dermatol. 2012;132:S97\u2013107.","journal-title":"J Invest Dermatol."},{"issue":"1","key":"1293_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1293_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"ATVT Haikarainen","year":"2019","unstructured":"Haikarainen ATVT, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15\u201332. https:\/\/doi.org\/10.1007\/s40259-019-00333-w.","journal-title":"BioDrugs."},{"key":"1293_CR35","unstructured":"FDA. Drug approval package: olumiant (baricitinib). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000Lbl.pdf. Accessed 20 Jul 2019."},{"key":"1293_CR36","unstructured":"Tofacitinib highlights of prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed 20 Jul 2019."},{"key":"1293_CR37","unstructured":"Ruxolitinib highlights of prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202192s017lbl.pdf. Accessed 20 Jul 2019."},{"issue":"9","key":"1293_CR38","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139. https:\/\/doi.org\/10.1038\/nm.3645.","journal-title":"Nat Med"},{"issue":"9","key":"1293_CR39","doi-asserted-by":"publisher","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","volume":"1","author":"S Harel","year":"2015","unstructured":"Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. https:\/\/doi.org\/10.1126\/sciadv.1500973.","journal-title":"Sci Adv."},{"issue":"11","key":"1293_CR40","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1073\/pnas.89.11.5068","volume":"89","author":"K Turksen","year":"1992","unstructured":"Turksen K, Kupper T, Degenstein L, Williams I, Fuchs E. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci USA. 1992;89(11):5068\u201372. https:\/\/doi.org\/10.1073\/pnas.89.11.5068.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"1293_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/jid.2011.274","volume":"132","author":"MH Kwack","year":"2012","unstructured":"Kwack MH, Ahn JS, Kim MK, Kim JC, Sung YK. Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. J Invest Dermatol. 2012;132(1):43\u20139. https:\/\/doi.org\/10.1038\/jid.2011.274.","journal-title":"J Invest Dermatol."},{"issue":"1","key":"1293_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0625.2007.00643.x","volume":"17","author":"M Yu","year":"2008","unstructured":"Yu M, Kissling S, Freyschmidt-Paul P, Hoffmann R, Shapiro J, McElwee KJ. Interleukin-6 cytokine family member oncostatin M is a hair-follicle-expressed factor with hair growth inhibitory properties. Exp Dermatol. 2008;17(1):12\u20139. https:\/\/doi.org\/10.1111\/j.1600-0625.2007.00643.x.","journal-title":"Exp Dermatol"},{"issue":"Suppl 2","key":"1293_CR43","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576.","journal-title":"Ann Rheum Dis."},{"key":"1293_CR44","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT.S172638","volume":"12","author":"K Triyangkulsri","year":"2018","unstructured":"Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323\u201335. https:\/\/doi.org\/10.2147\/DDDT.S172638.","journal-title":"Drug Des Devel Ther."},{"issue":"9","key":"1293_CR45","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307. https:\/\/doi.org\/10.4049\/jimmunol.0902819.","journal-title":"J Immunol."},{"issue":"4","key":"1293_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351\u20135. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.015.","journal-title":"EBioMedicine."},{"issue":"15","key":"1293_CR47","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317. https:\/\/doi.org\/10.1182\/blood-2009-04-214957.","journal-title":"Blood"},{"issue":"4","key":"1293_CR48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","volume":"67","author":"N Punwani","year":"2012","unstructured":"Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2011.12.018.","journal-title":"J Am Acad Dermatol"},{"key":"1293_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41. https:\/\/doi.org\/10.1186\/1476-9255-7-41.","journal-title":"J Inflamm (Lond)"},{"issue":"7","key":"1293_CR50","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1003668.","journal-title":"J Immunol."},{"issue":"9","key":"1293_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00403-017-1777-5","volume":"309","author":"J Meephansan","year":"2017","unstructured":"Meephansan J, Thummakriengkrai J, Ponnikorn S, Yingmema W, Deenonpoe R, Suchonwanit P. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res. 2017;309(9):729\u201338. https:\/\/doi.org\/10.1007\/s00403-017-1777-5.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1293_CR52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136. https:\/\/doi.org\/10.1111\/jdv.15489.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1293_CR53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines\u2013part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.032.","journal-title":"J Am Acad Dermatol."},{"key":"1293_CR54","unstructured":"Aclaris Therapeutics announces phase 2 clinical trial of ATI-502 topical in patients with alopecia areata did not meet endpoints. Aclaris Therapeutics. 2019. https:\/\/investor.aclaristx.com\/news-releases\/news-release-details\/aclaris-therapeutics-announces-phase-2-clinical-trial-ati-502. Accessed 2 Feb 2020."},{"issue":"15","key":"1293_CR55","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. https:\/\/doi.org\/10.1172\/jci.insight.89776.","journal-title":"JCI Insight."},{"issue":"15","key":"1293_CR56","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. https:\/\/doi.org\/10.1172\/jci.insight.89790.","journal-title":"JCI Insight."},{"issue":"1","key":"1293_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"BG Craiglow","year":"2017","unstructured":"Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.006.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1293_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1293_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol. 2017;153(6):600\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0001.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"1293_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","volume":"77","author":"HS Park","year":"2017","unstructured":"Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017;77(5):978\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.027.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1293_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403\u2013404e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"1293_CR62","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/09546634.2018.1466024","volume":"29","author":"JS Lee","year":"2018","unstructured":"Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatolog Treat. 2018;29(8):819\u201322. https:\/\/doi.org\/10.1080\/09546634.2018.1466024.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1293_CR63","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138(7):1539\u201345. https:\/\/doi.org\/10.1016\/j.jid.2018.01.032.","journal-title":"J Invest Dermatol."},{"issue":"12","key":"1293_CR64","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.14192","volume":"57","author":"L Bokhari","year":"2018","unstructured":"Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57(12):1464\u201370. https:\/\/doi.org\/10.1111\/ijd.14192.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1293_CR65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","volume":"235","author":"N Almutairi","year":"2019","unstructured":"Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology. 2019;235(2):130\u20136. https:\/\/doi.org\/10.1159\/000494613.","journal-title":"Dermatology"},{"issue":"5","key":"1293_CR66","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.013.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1293_CR67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bjd.12517","volume":"169","author":"B Strober","year":"2013","unstructured":"Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12\u00a0weeks of psoriasis treatment. Br J Dermatol. 2013;169(5):992\u20139. https:\/\/doi.org\/10.1111\/bjd.12517.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1293_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2\u00a0years median time in treatment. J Rheumatol. 2019;46(1):7\u201318. https:\/\/doi.org\/10.3899\/jrheum.171361.","journal-title":"J Rheumatol"},{"issue":"6","key":"1293_CR69","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1293_CR70","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u00a0years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457.","journal-title":"Ann Rheum Dis."},{"issue":"6024","key":"1293_CR71","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"issue":"2","key":"1293_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","volume":"47","author":"JR Maneiro","year":"2017","unstructured":"Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47(2):149\u201356. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.007.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1293_CR73","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831\u201341. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205847.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1293_CR74","first-page":"614","volume":"35","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Lee EB, Martin G, Mariette X, Terry KK, Chen Y, et al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme. Clin Exp Rheumatol. 2017;35(4):614\u201322.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1293_CR75","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2217\/imt.15.69","volume":"7","author":"JD Hamilton","year":"2015","unstructured":"Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043\u201358. https:\/\/doi.org\/10.2217\/imt.15.69.","journal-title":"Immunotherapy."},{"issue":"5","key":"1293_CR76","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3324.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"1293_CR77","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277\u201387. https:\/\/doi.org\/10.1016\/j.jaci.2015.06.032.","journal-title":"J Allergy Clin Immunol."},{"issue":"8","key":"1293_CR78","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","volume":"5","author":"J Chung","year":"2019","unstructured":"Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep. 2019;5(8):643\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2019.03.019.","journal-title":"JAAD Case Rep."},{"key":"1293_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14880","author":"N Kanda","year":"2019","unstructured":"Kanda N, Koto M, Hoashi T, Saeki H. Case of alopecia areata during dupilumab treatment for atopic dermatitis. J Dermatol. 2019. https:\/\/doi.org\/10.1111\/1346-8138.14880.","journal-title":"J Dermatol"},{"issue":"9","key":"1293_CR80","first-page":"532","volume":"43","author":"D D\u2019Ippolito","year":"2018","unstructured":"D\u2019Ippolito D, Pisano M. Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. P T. 2018;43(9):532\u20135.","journal-title":"P T."},{"issue":"5","key":"1293_CR81","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X10374216","volume":"3","author":"EJ Scherl","year":"2010","unstructured":"Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Therap Adv Gastroenterol. 2010;3(5):321\u20138. https:\/\/doi.org\/10.1177\/1756283X10374216.","journal-title":"Therap Adv Gastroenterol."},{"issue":"1","key":"1293_CR82","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1111\/pde.13699","volume":"36","author":"A Aleisa","year":"2019","unstructured":"Aleisa A, Lim Y, Gordon S, Her MJ, Zancanaro P, Abudu M, et al. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2019;36(1):e44\u20135. https:\/\/doi.org\/10.1111\/pde.13699.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1293_CR83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd1989","volume":"5","author":"L Moreland","year":"2006","unstructured":"Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5(3):185\u20136. https:\/\/doi.org\/10.1038\/nrd1989.","journal-title":"Nat Rev Drug Discov."},{"key":"1293_CR84","unstructured":"Abatacept highlights of prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125118s171lbl.pdf. Accessed 20 Jul 2019."},{"issue":"2","key":"1293_CR85","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1523-1747.2002.01811.x","volume":"119","author":"JM Carroll","year":"2002","unstructured":"Carroll JM, McElwee KJLEK, Byrne MC, Sundberg JP. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol. 2002;119(2):392\u2013402. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.01811.x.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1293_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00063030-200620010-00004","volume":"20","author":"PS Hervey","year":"2006","unstructured":"Hervey PS, Keam SJ. Abatacept. BioDrugs. 2006;20(1):53\u201361. https:\/\/doi.org\/10.2165\/00063030-200620010-00004(discussion 2).","journal-title":"BioDrugs."},{"issue":"3","key":"1293_CR87","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjd.12397","volume":"169","author":"A Trink","year":"2013","unstructured":"Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690\u20134. https:\/\/doi.org\/10.1111\/bjd.12397.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1293_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1941738110366385","volume":"2","author":"BJ Cole","year":"2010","unstructured":"Cole BJ, Seroyer ST, Filardo G, Bajaj S, Fortier LA. Platelet-rich plasma: where are we now and where are we going? Sports Health. 2010;2(3):203\u201310. https:\/\/doi.org\/10.1177\/1941738110366385.","journal-title":"Sports Health."},{"issue":"5 Suppl Skin Re","key":"1293_CR89","first-page":"4","volume":"8","author":"H Sundaram","year":"2009","unstructured":"Sundaram H, Mehta RC, Norine JA, Kircik L, Cook-Bolden FE, Atkin DH, et al. Topically applied physiologically balanced growth factors: a new paradigm of skin rejuvenation. J Drugs Dermatol. 2009;8(5 Suppl Skin Rejuenation):4\u201313.","journal-title":"J Drugs Dermatol."},{"key":"1293_CR90","doi-asserted-by":"publisher","first-page":"6901983","DOI":"10.1155\/2018\/6901983","volume":"2018","author":"MS Hu","year":"2018","unstructured":"Hu MS, Borrelli MR, Lorenz HP, Longaker MT, Wan DC. Mesenchymal stromal cells and cutaneous wound healing: a comprehensive review of the background, role, and therapeutic potential. Stem Cells Int. 2018;2018:6901983. https:\/\/doi.org\/10.1155\/2018\/6901983.","journal-title":"Stem Cells Int."},{"issue":"7 Pt 1","key":"1293_CR91","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1524-4725.2012.02394.x","volume":"38","author":"ZJ Li","year":"2012","unstructured":"Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38(7 Pt 1):1040\u20136. https:\/\/doi.org\/10.1111\/j.1524-4725.2012.02394.x.","journal-title":"Dermatol Surg"},{"key":"1293_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12437","author":"MA El Taieb","year":"2017","unstructured":"El Taieb MA, Ibrahim H, Nada EA, Seif Al-Din M. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: a trichoscopic evaluation. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12437.","journal-title":"Dermatol Ther."},{"key":"1293_CR93","doi-asserted-by":"publisher","DOI":"10.4172\/2167-0951.1000116","author":"R d\u2019Ovidio","year":"2014","unstructured":"d\u2019Ovidio R, Roberto M. Limited effectiveness of platelet-rich-plasma treatment on chronic severe alopecia areata [letter]. Hair Ther Transpl. 2014. https:\/\/doi.org\/10.4172\/2167-0951.1000116.","journal-title":"Hair Ther Transpl"},{"issue":"1","key":"1293_CR94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","volume":"311","author":"D Mikhaylov","year":"2019","unstructured":"Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019;311(1):29\u201336. https:\/\/doi.org\/10.1007\/s00403-018-1876-y.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1293_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/jidsymp.2015.32","volume":"17","author":"R Katikaneni","year":"2015","unstructured":"Katikaneni R, Seymour AW, Gulati R, Ponnapakkam T, Gensure RC. Therapy for alopecia areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain. J Investig Dermatol Symp Proc. 2015;17(2):13\u20135. https:\/\/doi.org\/10.1038\/jidsymp.2015.32.","journal-title":"J Investig Dermatol Symp Proc."},{"issue":"5","key":"1293_CR96","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41375-018-0290-y","volume":"33","author":"TT Wang","year":"2019","unstructured":"Wang TT, Yang J, Zhang Y, Zhang M, Dubois S, Conlon KC, et al. IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability. Leukemia. 2019;33(5):1243\u201355. https:\/\/doi.org\/10.1038\/s41375-018-0290-y.","journal-title":"Leukemia"},{"issue":"9","key":"1293_CR97","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2019.1604688","volume":"20","author":"V Ramachandran","year":"2019","unstructured":"Ramachandran V, Cline A, Feldman SR, Strowd LC. Evaluating crisaborole as a treatment option for atopic dermatitis. Expert Opin Pharmacother. 2019;20(9):1057\u201363. https:\/\/doi.org\/10.1080\/14656566.2019.1604688.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1293_CR98","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594\u2013609. https:\/\/doi.org\/10.1007\/s12325-017-0542-7.","journal-title":"Adv Ther."},{"issue":"6","key":"1293_CR99","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1346-8138.2009.00647.x","volume":"36","author":"S Inui","year":"2009","unstructured":"Inui S, Nakajima T, Toda N, Itami S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J Dermatol. 2009;36(6):323\u20137. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00647.x.","journal-title":"J Dermatol"},{"issue":"12","key":"1293_CR100","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1346-8138.2007.00401.x","volume":"34","author":"S Inui","year":"2007","unstructured":"Inui S, Nakajima T, Itami S. Two cases of alopecia areata responsive to fexofenadine. J Dermatol. 2007;34(12):852\u20134. https:\/\/doi.org\/10.1111\/j.1346-8138.2007.00401.x.","journal-title":"J Dermatol"},{"issue":"12","key":"1293_CR101","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/j.1346-8138.2012.01571.x","volume":"39","author":"Y Nonomura","year":"2012","unstructured":"Nonomura Y, Otsuka A, Miyachi Y, Kabashima K. Case of intractable ophiasis type of alopecia areata presumably improved by fexofenadine. J Dermatol. 2012;39(12):1063\u20134. https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01571.x.","journal-title":"J Dermatol"},{"issue":"2","key":"1293_CR102","first-page":"71","volume":"5","author":"C Howard","year":"2016","unstructured":"Howard C, Do Young K. Use of lasers in the treatment of alopecia areata. Med Lasers Eng Basic Res Clini Appl. 2016;5(2):71\u20136.","journal-title":"Med Lasers Eng Basic Res Clini Appl."},{"issue":"7","key":"1293_CR103","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1365-4632.2009.04230.x","volume":"49","author":"KH Yoo","year":"2010","unstructured":"Yoo KH, Kim MN, Kim BJ, Kim CW. Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol. 2010;49(7):845\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04230.x.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1293_CR104","first-page":"300","volume":"11","author":"I Venten","year":"2006","unstructured":"Venten I, Hess N, Hirschmuller A, Altmeyer P, Brockmeyer N. Treatment of therapy-resistant alopecia areata with fumaric acid esters. Eur J Med Res. 2006;11(7):300\u20135.","journal-title":"Eur J Med Res."},{"issue":"3","key":"1293_CR105","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1684\/ejd.2018.3249","volume":"28","author":"L Niculescu","year":"2018","unstructured":"Niculescu L, Heppt MV, Varga R, Steckmeier S, Wolff H, Tietze JK. Retrospective analysis of the application of fumaric acid esters in 13 patients with alopecia areata. Eur J Dermatol. 2018;28(3):376\u20137. https:\/\/doi.org\/10.1684\/ejd.2018.3249.","journal-title":"Eur J Dermatol."},{"issue":"6","key":"1293_CR106","doi-asserted-by":"publisher","first-page":"755","DOI":"10.5021\/ad.2017.29.6.755","volume":"29","author":"JW Choi","year":"2017","unstructured":"Choi JW, Suh DW, Lew BL, Sim WY. Simvastatin\/ezetimibe therapy for recalcitrant alopecia areata: an open prospective study of 14 patients. Ann Dermatol. 2017;29(6):755\u201360. https:\/\/doi.org\/10.5021\/ad.2017.29.6.755.","journal-title":"Ann Dermatol"},{"issue":"1","key":"1293_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1567-5688(01)00010-1","volume":"3","author":"F Mach","year":"2002","unstructured":"Mach F. Immunosuppressive effects of statins. Atheroscler Suppl. 2002;3(1):17\u201320.","journal-title":"Atheroscler Suppl."},{"issue":"5","key":"1293_CR108","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4070\/kcj.2011.41.5.253","volume":"41","author":"MS Oh","year":"2011","unstructured":"Oh MS, Min YJ, Kwon JE, Cho EJ, Kim JE, Lee WS, et al. Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients. Korean Circ J. 2011;41(5):253\u20138. https:\/\/doi.org\/10.4070\/kcj.2011.41.5.253.","journal-title":"Korean Circ J."},{"issue":"2","key":"1293_CR109","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2014.11.006","volume":"72","author":"C Lattouf","year":"2015","unstructured":"Lattouf C, Jimenez JJ, Tosti A, Miteva M, Wikramanayake TC, Kittles C, et al. Treatment of alopecia areata with simvastatin\/ezetimibe. J Am Acad Dermatol. 2015;72(2):359\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2014.11.006.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1293_CR110","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208\u201319. https:\/\/doi.org\/10.1016\/j.jmb.2016.12.005.","journal-title":"J Mol Biol"},{"issue":"2","key":"1293_CR111","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1523-1747.2002.01849.x","volume":"119","author":"R Ruckert","year":"2002","unstructured":"Ruckert R, Brandt K, Hofmann U, Bulfone-Paus S, Paus R. IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. J Invest Dermatol. 2002;119(2):370\u20136. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.01849.x.","journal-title":"J Invest Dermatol."},{"issue":"7","key":"1293_CR112","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","volume":"150","author":"E Castela","year":"2014","unstructured":"Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2014.504.","journal-title":"JAMA Dermatol."},{"key":"1293_CR113","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13812","author":"JE Kim","year":"2018","unstructured":"Kim JE, Oh JH, Woo YJ, Jung JH, Jeong KH, Kang H. Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models. Exp Dermatol. 2018. https:\/\/doi.org\/10.1111\/exd.13812.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1293_CR114","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13287-018-0889-y","volume":"9","author":"R Anderi","year":"2018","unstructured":"Anderi R, Makdissy N, Azar A, Rizk F, Hamade A. Cellular therapy with human autologous adipose-derived adult cells of stromal vascular fraction for alopecia areata. Stem Cell Res Ther. 2018;9(1):141. https:\/\/doi.org\/10.1186\/s13287-018-0889-y.","journal-title":"Stem Cell Res Ther."},{"issue":"9","key":"1293_CR115","first-page":"5285","volume":"11","author":"X Lin","year":"2019","unstructured":"Lin X, Meng X, Song Z. Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy. Am J Transl Res. 2019;11(9):5285\u2013300.","journal-title":"Am J Transl Res."},{"issue":"1","key":"1293_CR116","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jaad.2017.07.051","volume":"78","author":"TY Tsai","year":"2018","unstructured":"Tsai TY, Huang YC. Vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(1):207\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.051.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1293_CR117","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/ced.12241","volume":"39","author":"YY Lim","year":"2014","unstructured":"Lim YY, Kim SY, Kim HM, Li KS, Kim MN, Park KC, et al. Potential relationship between the canonical Wnt signalling pathway and expression of the vitamin D receptor in alopecia. Clin Exp Dermatol. 2014;39(3):368\u201375. https:\/\/doi.org\/10.1111\/ced.12241.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1293_CR118","first-page":"616","volume":"14","author":"AA Cerman","year":"2015","unstructured":"Cerman AA, Solak SS, Altunay I, Kucukunal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14(6):616\u201320.","journal-title":"J Drugs Dermatol"},{"key":"1293_CR119","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12464","author":"T Narang","year":"2017","unstructured":"Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Ther. 2017. https:\/\/doi.org\/10.1111\/dth.12464.","journal-title":"Dermatol Ther."},{"issue":"1","key":"1293_CR120","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cei.13158","volume":"195","author":"F De Luca","year":"2019","unstructured":"De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195(1):74\u201385. https:\/\/doi.org\/10.1111\/cei.13158.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1293_CR121","doi-asserted-by":"publisher","first-page":"e0215206","DOI":"10.1371\/journal.pone.0215206","volume":"14","author":"D Pinto","year":"2019","unstructured":"Pinto D, Sorbellini E, Marzani B, Rucco M, Giuliani G, Rinaldi F. Scalp bacterial shift in alopecia areata. PLoS One. 2019;14(4):e0215206. https:\/\/doi.org\/10.1371\/journal.pone.0215206.","journal-title":"PLoS One"},{"issue":"6","key":"1293_CR122","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14728222.2018.1481504","volume":"22","author":"A Borde","year":"2018","unstructured":"Borde A, Astrand A. Alopecia areata and the gut-the link opens up for novel therapeutic interventions. Expert Opin Ther Targets. 2018;22(6):503\u201311. https:\/\/doi.org\/10.1080\/14728222.2018.1481504.","journal-title":"Expert Opin Ther Targets."},{"key":"1293_CR123","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14309\/crj.2017.107","volume":"4","author":"D Rebello","year":"2017","unstructured":"Rebello D, Wang E, Yen E, Lio PA, Kelly CR. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J. 2017;4:107. https:\/\/doi.org\/10.14309\/crj.2017.107.","journal-title":"ACG Case Rep J."},{"key":"1293_CR124","unstructured":"FDA. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation\u2014screening and testing of stool donors for multi-drug resistant organisms. 2019. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation. Accessed 20 Jan 2019."},{"issue":"8","key":"1293_CR125","doi-asserted-by":"publisher","first-page":"e0161174","DOI":"10.1371\/journal.pone.0161174","volume":"11","author":"S Wang","year":"2016","unstructured":"Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016;11(8):e0161174. https:\/\/doi.org\/10.1371\/journal.pone.0161174.","journal-title":"PLoS One"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01293-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:58:49Z","timestamp":1619049529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01293-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01293-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"22 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Aunna Pourang MD and Natasha Atanaskova Mesinkovska MD, PhD have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}